Quote for Vaccine purchasing plan

Recombinant hepatitis B vaccine for children 0 - 10 years old: 0.5 ml (10mcg)

Groups 1,4,5

Pure hepatitis B virus surface ≈ 10µg/0.5ml

Inject

Injection

Box/ Vial/ Tube/ Syringe/ Dose

50

Recombinant hepatitis B vaccine for people from 10 years old: 1 ml (20mcg)

Groups 1,4,5

Pure hepatitis B virus surface ≈ 20µg/1ml

Inject

Injection

Box/ Vial/ Tube/ Syringe/ Dose

3.000

Seasonal influenza vaccine (quadrivalent, fragment vaccine, inactivated for children 6 months and older and adults)

Groups 1,4,5

Concentration, content: Each 0.5 ml of vaccine (surface antigen, inactivated) contains: A/Victoria/4897/2022 (H1N1)pdm09-like strain (A/Victoria/4897/2022, IVR-238) 15 mcg haemagglutinin, A/Croatia/10136RV/2023 (H3N2)-like strain (A/Croatia/10136RV/2023, B/Phuket/3073/2013-like strain (B/Phuket/3073/2013, wild type) 15 mcg haemagglutinin

Inject

Injection

Box/ Vial/ Tube/ Syringe/ Dose

3.000

Purified Vero cell rabies vaccine

Groups 1,4,5

Inactive rabies virus (L. Pasteur 2061/Vero is propagated on Vero cells) ≥ 2.5 IU

Inject

East dried powder injected

Vial/dose

2.000

Refined rabies serum

Groups 1,4,5

Antibodies against rabies virus 1000 IU/ 5ml vial

Inject

Injection solution

Vial/Tube/Syringe

30

Vaccine to prevent chickenpox virus (live attenuated vaccine)

Groups 1,4,5

Oka/Merck varicella virus, live, attenuated >= 1350 PFU/vial Concentration/content: >=1350 PFU/vial

Inject

East dried powder injected

Box/ Vial/ Tube/ Syringe/ Dose

600

Meningococcal ACWY vaccine

Groups 1,4,5

1 dose (0.5 ml): Mocca polysaccharide (serum group A) (unit price plus) 4 µg (mcg); Moco brain polysaccharide (serum C) (unit price plus) 4 µg (MCG); Mocca polysaccharide (serum medical group) (unit price plus) 4 µg (mcg); Mocca polysaccharide (Serum group W-135) (Collective unit price) 4 µg (MCG); - Diphtheria detoxification protein (polysaccharide plus protein for all serum groups)* (* The amount of diphtheria detox is the estimated amount and depends on the ratio between polysaccharide plus and protein) 48 µg (MCG)

Inject

Injection solution

Box/ Vial/ Tube/ Syringe/ Dose

300

Meningococcal B+C vaccine

Groups 1,4,5

Each dose of 0.5ml contains: Membrane meningococcal protein group B - 50mcg; Polysaccharide cerebral cerebral cerebral tissue group C: 50mcg

Inject

Injection solution

Box/ Vial/ Tube/ Syringe/ Dose

150

Vaccine to prevent group B meningococcal disease

Groups 1,4,5

Each dose (0.5 ml) contains: - Synthetic protein (fusion protein) NHBA NHBA NHBA Neisseria Meningitidis Group B recombinant: 50mcg. - Nada Nada Nada Nada Nada Nada Meningitidis group B recombinant: 50mcg. -Protein synthesized FHBP Neisseria meningitidis group B recombinant: 50mcg. - The external membrane bag from Neisseria meningitidis group B strain NZ98/254 is measured by the total amount of protein containing Pora P1.4: 25mcg

Inject

Injection solution

Box/ Vial/ Tube/ Syringe/ Dose

200

Japanese Encephalitis vaccine (live attenuated vaccine)

Groups 1,4,5

Each dose of 0.5ml of revert vaccine contains: Japanese encephalitis virus SA14-14-2, recombinant, living, reducing poison 4.0-5.8 log pfu

Inject

East dried powder injected

Box/ Vial/ Tube/ Syringe/ Dose

200

Live virus vaccine prevents measles, mumps, and rubella

Groups 1,4,5

Measles virus live, reduce poison (Schwarz strain)> = LG3 CCID50; Virus mumps live, reduces toxicity (Rit strain 4385)> = LG3.7 CCID50; Rubella virus live, reducing poison (Wistar strain to 27/3)> = LG3 CCID51

Inject

East dried powder injected

Box/ Vial/ Tube/ Syringe/ Dose

500

Pneumococcal vaccine prevents 20 dangerous types of pneumococcal bacteria (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F).

Groups 1,4,5

Each single dose of 0.5 ml: tube serum 1 polysaccharid pneumococcal bacteria 2.2 mcg; Type 3 polysaccharid pneumococcal pneumococcal bacteria 2.2 mcg; Type 4 polysaccharide pneumococcal pneumococcal bacteria 2.2 mcg; Type 5 polysaccharide pneumococcal bacteria 2.2 mcg; Type 6A polysaccharide pneumococcal pneumococcal bacteria 2.2 mcg; Type 6b polysaccharid pneumococcal pneumococcal pneumococcal pneumococcal pneumococcal; Type 7f polysaccharide pneumococcal bacteria 2.2 mcg; Type 8 polysaccharide pneumococcal bacteria 2.2 mcg; Type 9V polysaccharide pneumococcal pneumococcal bacteria 2.2 mcg; Type 10A polysaccharid pneumococcal pneumococcal bacteria 2.2 mcg; Type 11A polysaccharide pneumococcal bacteria 2.2 mcg; Type 12f polysaccharide pneumococcal bacteria 2.2 mcg; Type 14 polysaccharid pneumococcal pneumococcal bacteria 2.2 mcg; Type 15b polysaccharide pneumococcal bacteria 2.2 mcg; Type 18C polysaccharide pneumococcal bacteria 2.2 mcg; Type 19A polysaccharid pneumococcal pneumococcal bacteria 2.2 mcg; Type 19f polysaccharide pneumococcal pneumococcal bacteria 2.2 mcg; Type 22f polysaccharide pneumococcal bacteria 2.2 mcg; Type 23F polysaccharide pneumococcal bacteria 2.2 mcg; Type 33f polysaccharide pneumococcal bacteria 2.2 mcg; (20 Collection of pneumococcal bacteria - Saccharid plus CRM197)

Inject

Injection solution

Box/ Vial/ Tube/ Syringe/ Dose

600

23-type invasive pneumococcal vaccine, including: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F.

Groups 1,4,5

Each vaccine (0.5 ml) contains 25mcg per type of 23 types of polysaccharide serum of Danish pneumococcal: 1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10A, 11A, 12F, 14, 17F, 18C, 19A, 19F, 19F, 20F, 22F, 23F, 33F

Inject

Injection solution

Box/ Vial/ Tube/ Syringe/ Dose

600

Pneumococcal Vaccine Prevents 15 common types of pneumococcal bacteria (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F) that cause pneumonia, meningitis, septicemia, and otitis media.

Groups 1,4,5

Each dose (0.5 ml) contains 2 mcg of pneumococcal polysaccharides of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F and 4 mcg of serotype 6B, conjugated to the carrier protein CRM197, and adsorbed onto the substrate. aluminum phosphate salt adjuvant Concentration/content: Each dose (0.5ml) contains 2 mcg of pneumococcal polysaccharides of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F and 4 mcg of serotype 6B, combined with carrier protein CRM197, and adsorbed on aluminum phosphate adjuvant

Inject

Injection solution

Box/ Vial/ Tube/ Syringe/ Dose

600

Vaccine to prevent cervical cancer of 9 types

Groups 1,4,5

Each dose of 0.5ml contains 30mcg protein L1 HPV type 6; 40mcg protein L1 HPV type 11; 60mcg protein L1 HPV type 16; 40mcg protein l1 hpv type 18; 20mcg protein L1 HPV for each type 31,33,45,52 and 58

Inject

Injection solution

Box/ Vial/ Tube/ Syringe/ Dose

300

Combined vaccine to prevent diphtheria - tetanus - acellular pertussis

Groups 1,4,5

One dose (0.5ml) contains: Diphore detox ≥ 2iu; Tetanintic detox ≥ 20iu; Bordetella pertussis antigens include 8MCG pertussis detoxification; Conducting red blood cells in 8mcg and pertactin 2.5mcg

Inject

Injection solution

Box/ Vial/ Tube/ Syringe/ Dose

300

Adsorbed tetanus vaccine

Groups 1,4,5

Detoxification refined tetanus ≥ 40 IU/0.5ml

Inject

Injection solution

Box/ Vial/ Tube/ Syringe/ Dose

5.000

Inactivated hepatitis A and recombinant hepatitis B vaccines

Groups 1,4,5

Each dose of 1ml contains hepatitis A virus antigen (HM175 Strain) 720 Elisa Units; R-DNA Hepatitis B Virus Surface Antigen (HBsAg) 20mcg

Inject

Injection solution

Box/ Vial/ Tube/ Syringe/ Dose

1.000

Vaccine to prevent diphtheria and tetanus

Groups 1,4,5

Each dose of 0.5ml of vaccine containing: Detoxification of pure tetanus at least 20 ĐVQT; Diphipo detoxifies at least 2 ĐVQT

Inject

Injection solution

Box/ Vial/ Tube/ Syringe/ Dose

1.000

Dengue prevention vaccine

Groups 1,4,5

Each vaccine 0.5ml after reconciliation contains: serum type 1 virus dengue (dengue fever) (living, reducing toxicity) ≥ 3.3 log 10 pfu; Serum tube 2 virus dengue (dengue virus) (living, reducing poison) ≥ 2.7 log 10 pfu; Serum tube 3 virus dengue (dengue virus) (living, reducing poison) ≥ 4.0 log 10 pfu; Serum tube 4 Virus Dengue (Dengue Virus) (Living, reducing poison) ≥ 4.5 log 10 pfu

Inject

Injected powder

Box/ Vial/ Tube/ Syringe/ Dose

600

Vaccines prevent dangerous respiratory infections caused by respiratory syncytial virus

Group 1

After reconciliation, 1 dose (0.5ml) contains 120mcg of RSVPREF3 antigen that is added with AS01E. RSVPREF3: Glycoprotein F of the respiratory microscopic microorganisms (RSV) is stable in the form of consolidated currency RSVPREF3. AS01E supplementary system includes Quillaja Saponaria Molina extract, segment 21 (QS-21) 25MCG and 3-O-DESACYL-4’-Monophosphoryl Lipid A (MPL) from Salmonella Minnesota 25 mcg

Inject

Powder and phase mixture

Box/ Vial/ Tube/ Syringe/ Dose

100

Vaccine to prevent shingles (shingles)

Groups 1,4,5

Each dose of 0.5ml after reconciliation contains 50mcg antigens GE recombinant of the Varicella Zoster virus (VZV) is supplemented with AS01B

Inject

Powder and phase mixture

Box/ Vial/ Tube/ Syringe/ Dose

200

Typhoid vaccine

Groups 1,4,5

Pre-intensive syringe 1 dose of vaccines (0.5 ml) contains: refined from the polysaccharide shell of Salmonella Typhi (Ty2) 25mcg bacteria.

Inject

Injection solution

Box/ Vial/ Tube/ Syringe/ Dose

200